Literature DB >> 12626528

Cutting edge: Toll-like receptor 9 expression is not required for CpG DNA-aided cross-presentation of DNA-conjugated antigens but essential for cross-priming of CD8 T cells.

Antje Heit1, Tobias Maurer, Hubertus Hochrein, Stefan Bauer, Katharina M Huster, Dirk H Busch, Hermann Wagner.   

Abstract

Covalent linkage of immunostimulatory CpG DNA to OVA results in CpG DNA-aided cross-presentation of OVA by dendritic cells (DCs). In vivo, cross-presentation is conditional for cross-priming of OVA-specific CD8 T cells. In this study, we investigated the involvement of the CpG DNA receptor Toll-like receptor (TLR)9 in CpG DNA-aided cross-presentation and cross-priming. Although CpG DNA-aided cross-presentation is not altered in TLR9-deficient cells, TLR9 is required for maturation of APC allowing cross-priming, as resulting in CTL function. These findings imply that TLR9 does not trigger endocytosis of CpG-OVA conjugates, but activates DCs downstream of endocytosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12626528     DOI: 10.4049/jimmunol.170.6.2802

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  22 in total

1.  AIMing 2 defend against intracellular pathogens.

Authors:  Arthur M Krieg
Journal:  Nat Immunol       Date:  2010-05       Impact factor: 25.606

2.  CD8+-T-cell-dependent control of Trypanosoma cruzi infection in a highly susceptible mouse strain after immunization with recombinant proteins based on amastigote surface protein 2.

Authors:  Adriano F S Araújo; Bruna C G de Alencar; José Ronnie C Vasconcelos; Meire I Hiyane; Cláudio R F Marinho; Marcus L O Penido; Silvia B Boscardin; Daniel F Hoft; Ricardo T Gazzinelli; Mauricio M Rodrigues
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

Authors:  Kathrin Kastenmüller; Ulrike Wille-Reece; Ross W B Lindsay; Lauren R Trager; Patricia A Darrah; Barbara J Flynn; Maria R Becker; Mark C Udey; Björn E Clausen; Botond Z Igyarto; Daniel H Kaplan; Wolfgang Kastenmüller; Ronald N Germain; Robert A Seder
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

4.  Optimised electroporation mediated DNA vaccination for treatment of prostate cancer.

Authors:  Sarfraz Ahmad; Garrett Casey; Paul Sweeney; Mark Tangney; Gerald C O'Sullivan
Journal:  Genet Vaccines Ther       Date:  2010-02-05

Review 5.  Dendritic cell-targeted vaccines--hope or hype?

Authors:  Wolfgang Kastenmüller; Kathrin Kastenmüller; Christian Kurts; Robert A Seder
Journal:  Nat Rev Immunol       Date:  2014-09-05       Impact factor: 53.106

6.  Presentation of soluble antigens to CD8+ T cells by CpG oligodeoxynucleotide-primed human naive B cells.

Authors:  Wei Jiang; Michael M Lederman; Clifford V Harding; Scott F Sieg
Journal:  J Immunol       Date:  2011-01-14       Impact factor: 5.422

7.  The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity.

Authors:  Jason Z Oh; Ross M Kedl
Journal:  J Immunol       Date:  2010-09-15       Impact factor: 5.422

Review 8.  Traditional biochemical assays for studying toll-like receptor 9.

Authors:  Cynthia A Leifer; William A Rose; Fernando Botelho
Journal:  J Immunoassay Immunochem       Date:  2013

9.  Delivery of Exogenous Antigens to Induce Cytotoxic CD8+ T Lymphocyte Responses.

Authors:  Julia Kim; Vandana Gambhir; Attiya Alatery; Sameh Basta
Journal:  J Biomed Biotechnol       Date:  2010-05-23

Review 10.  Vaccine adjuvants: putting innate immunity to work.

Authors:  Robert L Coffman; Alan Sher; Robert A Seder
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.